title: [Long-term administration of low-dose phosphodiesterase type 5 inhibitors for erectile dysfunction: an update].
abstract: Erectile dysfunction (ED) is a common disorder that affects the quality of life of both men and their partners. The phosphodiesterase type 5 inhibitor is the first-line drug for ED. Recent researches found that long-term administration of low-dose phosphodiesterase type 5 inhibitors to be a safe and effective therapy for ED, as well as for couples who may prefer more convenience and spontaneity in their sexual activities. Besides, it provides a new therapeutic option for refractory ED. Its action mechanism mainly involves the improvement of the endothelial function of penile vessels and/or maintenance of the function and number of smooth muscle cells. However, whether this therapy can maintain the improved erection function after drug withdrawal needs further studies.
authors.affiliation: Department of Urology, The Affiliated Hospital of Luzhou Medical College, Luzhou, Sichuan 646000, China. jiangrui@126.com
authors.forename: Rui
authors.initials: R
authors.lastname: Jiang
mesh_terms: D007172:Erectile Dysfunction / Q000188:drug therapy*; D006801:Humans; D008297:Male; D058986:Phosphodiesterase 5 Inhibitors / Q000008:administration & dosage* / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D058986:Phosphodiesterase 5 Inhibitors